The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Innate Pharma (Inst); Kyowa Hakko Kirin (Inst); Millennium (Inst)
First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.
 
Martine Bagot
No Relationships to Disclose
 
Madeleine Duvic
Research Funding - Innate Pharma (Inst)
 
Maarten Vermeer
Consulting or Advisory Role - Kyowa Hakko Kirin
Research Funding - TEVA (Inst)
 
Pierluigi Porcu
Research Funding - Innate Pharma (Inst)
 
Sean Whittaker
Research Funding - Innate Pharma (Inst)
 
Caroline Ram-Wolff
No Relationships to Disclose
 
Christine Paiva
Employment - Innate Pharma
Stock and Other Ownership Interests - Innate Pharma
 
Anne Marie-Cardine
No Relationships to Disclose
 
Cecile Bonnafous
Employment - Innate Pharma
Stock and Other Ownership Interests - Innate Pharma
 
Carine Paturel
Employment - Innate Pharma
Stock and Other Ownership Interests - Innate Pharma
 
Frederique Moriette
Employment - Innate Pharma
 
Robert Albert Zerbib
Employment - Innate Pharma
Stock and Other Ownership Interests - Innate Pharma
 
Armand Bensussan
No Relationships to Disclose
 
Helene Sicard
Employment - Innate Pharma
Stock and Other Ownership Interests - Innate Pharma
 
Korinna Pilz
Consulting or Advisory Role - Innate Pharma
 
Youn H. Kim
Consulting or Advisory Role - Actelion; Celgene; Eisai; Forty Seven; Galderma; Horizon Pharma; Kyowa Hakko Kirin; Millennium; miRagen; Seagen
Research Funding - Eisai (Inst); Innate Pharma (Inst); Kyowa Hakko Kirin (Inst); Merck (Inst); Millennium (Inst); Neumedicines (Inst); Seagen (Inst); Soligenix (Inst); TetraLogic Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Royalty for Chapters in UpToDate
Travel, Accommodations, Expenses - Innate Pharma